Abstract
Uveitis frequently develops in patients with ankylosing spondylitis (AS) and other autoimmune diseases. It is occasionally characterized by a severe recurrent course and untreatable with systemic glucocorticoids (GC) and standard immunosuppressive agents. The results of (mainly small) clinical trials, as well as some observations suggest that therapy with tumor necrosis factor-а (TNF-а) inhibitors is effective in such patients. There is the strongest evidence that they are beneficial in treating recurrent uveitis in patients with AS, infliximab having some efficacy advantages over etanercept and adalimumab. Accordingly, chronic uveitis in AS can be considered as an additional argument in favor of the use of TNF-а inhibitors. Furthermore, treatment with drugs of this group is warranted in severe uveitis refractory to GC and immunosuppressants. It is conceivable that in some forms of uveitis, for example, in patients with Behcet's disease, treatment with TNF-а inhibitors should be initiated at an earlier stage as the efficacy of standard immunosuppressants is generally limited
Highlights
Увеит — это распространенное заболевание различной этиологии, которое чаще развивается в молодом возрасте
It is conceivable that in some forms of uveitis, for example, in patients with Behcet's disease, treatment with tumor necrosis factor-α (TNF-α) inhibitors should be initiated at an earlier stage as the efficacy of standard immunosuppressants is generally limited
Например у пациентов с болезнью Бехчета, лечение ингибиторами фактора некроза опухоли α (ФНО α), возможно, следует начинать на более раннем этапе, так как эффективность стандартных иммуносупрессивных средств у них обычно ограничена
Summary
Увеит — это распространенное заболевание различной этиологии, которое чаще развивается в молодом возрасте. It is conceivable that in some forms of uveitis, for example, in patients with Behcet's disease, treatment with TNF-α inhibitors should be initiated at an earlier stage as the efficacy of standard immunosuppressants is generally limited. 1. Частота обострений увеита (на 100 человеко-лет) при лечении плацебо и ингибиторами ФНО α у больных АС 2. Число обострений увеита у больных с болезнью Бехчета до и после лечения циклоспорином или инфликсимабом нуждаются в комбинированной терапии ГК и иммуносупрессивными препаратами.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
